Lineage Cell Therapeutics, Inc. (LCTX) Social Stream
LINEAGE CELL THERAPEUTICS INC (LCTX) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering LINEAGE CELL THERAPEUTICS INC.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-12-02 | 5 | $8 | $5 | $6.4 | $0.982 | 551.73% |
| 2021-12-22 | 6 | $8 | $5 | $6.4 | $0.982 | 551.73% |
| 2022-06-03 | 5 | $8 | $6 | $6.75 | $0.982 | 587.37% |
| 2022-06-14 | 6 | $8 | $4 | $6.2 | $0.982 | 531.36% |
| 2022-08-16 | 7 | $8 | $4 | $6 | $0.982 | 511% |
| 2022-10-04 | 7 | $9 | $4 | $6.166 | $0.982 | 527.9% |
| 2023-05-12 | 8 | $9 | $4 | $6 | $0.982 | 511% |
| 2023-08-11 | 7 | $9 | $4 | $6 | $0.982 | 511% |
| 2023-10-19 | 6 | $7 | $4 | $5.5 | $0.982 | 460.08% |
| 2023-11-10 | 7 | $7 | $4 | $5.5 | $0.982 | 460.08% |
The Trend in the Analyst Price Target
LCTX's average price target has moved up $0.5 over the prior 37 months.
Over the past 37 weeks, LCTX's average upside potential has been 343.05%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-02-24 | 8 | 9 | 4 | 6.0 | 1.22 | 391.8% |
| 2023-04-26 | 8 | 9 | 4 | 6.0 | 1.35 | 344.44% |
| 2023-08-11 | 6 | 9 | 4 | 6.0 | 1.44 | 316.67% |
| 2023-08-11 | 7 | 7 | 4 | 5.5 | 1.44 | 281.94% |
| 2023-10-19 | 6 | 7 | 4 | 5.5 | 1.18 | 366.1% |
LCTX Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.29 | 6 | 0 | 1 | 0 | 0 | 7 |
The Trend in the Broker Recommendations
LCTX's average broker recommendation rating improved by 0 over the prior 26 weeks.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for LCTX as an investment opportunity.
- To contextualize these metrics, consider that out of all US stocks, LINEAGE CELL THERAPEUTICS INC's average analyst price target is higher than 54.87% of them.
- In the context of all US stocks, LINEAGE CELL THERAPEUTICS INC's upside potential (average analyst target price relative to current price) is greater than 930.03% of them.
- To contextualize these metrics, consider that out of stocks in the small market cap category, LINEAGE CELL THERAPEUTICS INC's number of analysts covering the stock is higher than 743.2% of them.
- In the context of stocks in the small market cap category, LINEAGE CELL THERAPEUTICS INC's variance in analysts' estimates is lower than -545.58% of them.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to LINEAGE CELL THERAPEUTICS INC are CVM, VXRT, and CRBU.
View All Top Stocks by Price Target
Make investment decisions regarding LCTX using the data that counts. Try POWR Ratings for free.